ProQR to host a conference call to discuss the top-line results of the Phase 2/3 Illuminate clinical trial of investigational RNA therapy sepofarsen in CEP20-mediated LCA10.
This website contains forward-looking statements about potential therapeutic uses and effects of ProQR Therapeutics’ products, including but not limited to our technologies.
At ProQR science is literally at the heart of what we do. Our passion lies in discovering the latest RNA technologies and translating them to life-changing treatments.
Featuring Dr. Byron Lam, Professor, Bascom Palmer Eye Institute, University of Miami School of Medicine
Hosted by Cantor Biotechnology Analysts Emma Nealon, Alethia Young
